EQUITY RESEARCH MEMO
BioTheraVision
Generated 5/10/2026
Executive Summary
Conviction (model self-assessment)30/100
BioTheraVision (BTV) is a pre-clinical stage ophthalmology company focused on repurposing known molecules to treat ocular diseases with high unmet need. Its lead candidates are BTV100 for dry eye disease and BT300 for post-surgical inflammation. The company's strategy leverages established safety profiles of repurposed drugs, potentially accelerating development. However, BTV is at a very early stage with no disclosed funding, valuation, or clinical data. The ophthalmic market is competitive, but BTV's approach could offer differentiated efficacy if preclinical studies are successful.
Upcoming Catalysts (preview)
- Q4 2026IND Filing for BTV10040% success
- Q2 2026Preclinical Data Readout for BT30050% success
- Q3 2026Series A Funding Announcement45% success
Locked sections
- · Pipeline Analysis
- · Competitive Landscape
- · Catalyst Calendar (full 12-month)
- · Bull Case
- · Bear Case
- · Counterfactual Scenarios
- · Valuation Notes
- · SEC Filing Highlights
- · Insider Activity
- · Literature Watch
- · Patent Landscape
- · Mechanism Cluster Map
- · Audio Briefing (5 min)